SCHEMBL23201178

SCHEMBL23201178

COc1cc(/C(N)=N\O)ccc1CN(C(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.42
ACHE P22303 5/20 0.38
BCHE P06276 4/20 0.38
LMNA P02545 3/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MTNR1A P48039 2/20 0.36
MTNR1B P49286 2/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23201180 1.00 RECQL (0.42) RECQLACHEBCHELMNAKMT2A
SCHEMBL26144387 0.94 RECQL (0.45) RECQLACHEBCHELMNAKMT2A
SCHEMBL26144388 0.81 PRSS1 (0.45) ACHEBCHEKMT2AMTNR1AMTNR1B
SCHEMBL407254 0.80 RECQL (0.42) RECQLACHEBCHELMNAKMT2A
SCHEMBL10170407 0.80 RECQL (0.42) RECQLACHEBCHELMNAKMT2A
SCHEMBL407253 0.80 RECQL (0.42) RECQLACHEBCHELMNAKMT2A
SCHEMBL18300436 0.80 GRM2 (0.38) RECQLMTNR1AMTNR1BHDAC8
SCHEMBL18300437 0.80 GRM2 (0.38) RECQLMTNR1AMTNR1BHDAC8
SCHEMBL6790938 0.79 RECQL (0.39) RECQLACHELMNAKMT2AMAPT
SCHEMBL26144389 0.77 ALDH1A1 (0.39) ACHEBCHEKMT2AMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 US disclosed
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-24 US disclosed
US-12195427-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-01-14 US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 US disclosed
EP-3802489-A2 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 RECQL 1704/4885ACHE 2670/4885BCHE 2766/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 RECQL 1704/4885ACHE 2670/4885BCHE 2766/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 RECQL 1704/4885ACHE 2670/4885BCHE 2766/4885
US-12195427-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 RECQL 1704/4885ACHE 2670/4885BCHE 2766/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 RECQL 1791/4885ACHE 2491/4885BCHE 2803/4885
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 RECQL 1704/4885ACHE 2670/4885BCHE 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.